Urogen Pharma (NASDAQ:URGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

URGN has been the topic of a number of other research reports. Oppenheimer Holdings, Inc. set a $32.00 price target on Urogen Pharma and gave the stock a “buy” rating in a report on Monday. Cowen and Company initiated coverage on Urogen Pharma in a report on Tuesday, May 30th. They set an “outperform” rating on the stock. Jefferies Group LLC initiated coverage on Urogen Pharma in a report on Tuesday, May 30th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Raymond James Financial, Inc. initiated coverage on Urogen Pharma in a report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $26.00.

Urogen Pharma (NASDAQ:URGN) opened at 17.58 on Friday. The stock has a 50 day moving average price of $17.90 and a 200 day moving average price of $17.59. Urogen Pharma has a one year low of $13.01 and a one year high of $20.02. The firm’s market cap is $40.52 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/18/urogen-pharma-urgn-downgraded-by-zacks-investment-research.html.

A number of large investors have recently made changes to their positions in the stock. Spark Investment Management LLC acquired a new stake in shares of Urogen Pharma during the second quarter worth $856,000. Menora Mivtachim Holdings LTD. acquired a new stake in shares of Urogen Pharma during the second quarter worth $2,331,000. LLBH Private Wealth Management LLC acquired a new stake in shares of Urogen Pharma during the second quarter worth $695,000. Alps Advisors Inc. acquired a new stake in shares of Urogen Pharma during the second quarter worth $195,000. Finally, Jennison Associates LLC acquired a new stake in shares of Urogen Pharma during the second quarter worth $3,168,000. 3.59% of the stock is currently owned by institutional investors.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.